Literature DB >> 20662309

The nocebo effect: a reason for patients' non-adherence to generic substitution?

J Weissenfeld1, S Stock, M Lüngen, A Gerber.   

Abstract

Substituting generic formulations of the same chemical agent is a common practice in German health care on the basis of so called rebate contracts. The substitution of a medication may affect the patients' adherence or result in adverse events. While adverse events which may be caused by the pharmacological activity of the agent itself can be explained, some non-specific side effects cannot be substantiated referring to pharmacological factors. These adverse reactions are summarized under the term nocebo effect. Since patients experiencing a nocebo effect can subsequently become non-adherent or even discontinue an appropiate therapy, the aim of this article is to study patients' adherence to generic substitution and the extent of the nocebo effect. In MEDLINE and EMBASE, a search was carried out for articles which were published between March 25th, 1989 and March 25th, 2009 by using the following search terms: generic substitution, adherence, non-adherence, non-persistence, rebate contracts, patients' attitude, nocebo, negative placebo effects, placebo adverse reactions, placebo induced side effects and negative placebo responses. In addition a manual search was performed in the reference lists of the articles retrieved. 14 studies met the inclusion and exclusion criteria and were included in this article. The generic substitution was generally accepted by over two thirds of the study populations. But up to 34% of patients being treated for psychological diseases confronted with a change of their medication had additional adverse events. On the basis of the studies analysed, the conclusion can be drawn that the nocebo effect can play a crucial role in the treatment of psychological diseases. Therefore, physicians and pharmacists should be responsible to prevent the nocebo effect through adequately educating the patients.

Entities:  

Mesh:

Year:  2010        PMID: 20662309

Source DB:  PubMed          Journal:  Pharmazie        ISSN: 0031-7144            Impact factor:   1.267


  20 in total

Review 1.  Nocebo in headaches: implications for clinical practice and trial design.

Authors:  Dimos D Mitsikostas
Journal:  Curr Neurol Neurosci Rep       Date:  2012-04       Impact factor: 5.081

Review 2.  Generic Substitution of Orphan Drugs for the Treatment of Rare Diseases: Exploring the Potential Challenges.

Authors:  Antonello Di Paolo; Elena Arrigoni
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

Review 3.  Improving Adherence to Treatment and Reducing Economic Costs of Hypertension: The Role of Olmesartan-Based Treatment.

Authors:  Francesco Vittorio Costa
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-07-10

4.  [Biosimilars and the nocebo effect].

Authors:  J Braun; S Tsiami; B Buehring; D Kiefer; I Andreica; X Baraliakos; U Kiltz
Journal:  Z Rheumatol       Date:  2020-04       Impact factor: 1.372

Review 5.  Safety of long-term bisphosphonate therapy for the management of osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Drugs       Date:  2011-04-16       Impact factor: 9.546

Review 6.  Nocebo phenomena in medicine: their relevance in everyday clinical practice.

Authors:  Winfried Häuser; Ernil Hansen; Paul Enck
Journal:  Dtsch Arztebl Int       Date:  2012-06-29       Impact factor: 5.594

7.  Informing About the Nocebo Effect Affects Patients' Need for Information About Antidepressants-An Experimental Online Study.

Authors:  Yvonne Nestoriuc; Yiqi Pan; Timm Kinitz; Ella Weik; Meike C Shedden-Mora
Journal:  Front Psychiatry       Date:  2021-04-27       Impact factor: 4.157

8.  Comparative effectiveness and costs of generic and brand-name gabapentin and venlafaxine in patients with neuropathic pain or generalized anxiety disorder in Spain.

Authors:  Antoni Sicras-Mainar; Javier Rejas-Gutiérrez; Ruth Navarro-Artieda
Journal:  Clinicoecon Outcomes Res       Date:  2015-06-04

9.  The nocebo effect of drugs.

Authors:  Sara Planès; Céline Villier; Michel Mallaret
Journal:  Pharmacol Res Perspect       Date:  2016-03-17

10.  Institutional framework for integrated Pharmaceutical Benefits Management: results from a systematic review.

Authors:  Tomasz Roman Hermanowski; Aleksandra Krystyna Drozdowska; Marta Kowalczyk
Journal:  Int J Integr Care       Date:  2015-09-29       Impact factor: 5.120

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.